Lakefront Biotherapeutics (GLPGF) Research & Development (2016 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Research & Development for 11 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Research & Development rose 81.14% year-over-year to -$36.2 million in Q1 2026; TTM through Mar 2026 was -$534.6 billion, a 49.09% decrease from a year earlier, with the FY2025 full-year figure at -$519.1 billion, down 42.96% from the prior year.
• Research & Development was -$36.2 million for Q1 2026 at Lakefront Biotherapeutics, up from -$534.4 billion in the prior quarter.
• Over five years, Research & Development peaked at $192.7 million in Q2 2025 and troughed at -$534.4 billion in Q4 2025.
• A 5-year average of -$109.8 billion and a median of -$192.2 million in 2025 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 196.58% in 2025, down 147.09% in 2025.
• Over 5 years, Research & Development stood at -$274.9 billion in 2022, then gained by 5.62% to -$259.4 billion in 2023, then plunged by 38.07% to -$358.2 billion in 2024, then slumped by 49.18% to -$534.4 billion in 2025, then surged by 99.99% to -$36.2 million in 2026.
• The last three Research & Development figures came in at -$36.2 million (Q1 2026), -$534.4 billion (Q4 2025), and -$396.8 million (Q3 2025), per Business Quant data.